Affiliations: UNM Carrie Tingley Bone Health Center, University of
New Mexico School of Medicine, Carrie Tingley Hospital, 1127 University Blvd.
NE, Albuquerque, NM 87102, USA. Tel.: +1 505 272 5214; Fax: +1 505 272 6500;
Abstract: Bisphosphonates (BPs) are used most commonly in children with
osteogenesis imperfecta, resulting in increased trabeculae and cortical
thickness, increased bone density as measured by DXA (Dual Energy X-ray
Absorptiometry), and improved vertebral morphology. Less well documented in
controlled trials are decrease in long bone fractures, improved strength and
motor function, and decreased pain . Outside of children with osteogenesis imperfecta, use of
bisphosphonates in children is increasing, all of which is off-label. This is
seen in children with other chronic conditions resulting in pediatric
osteoporosis and insufficiency fractures. Additional indications include
steroid dependency with progressive loss of bone density, avascular necrosis of
bone, and chronic regional pain syndrome. This review highlights the potential
benefits and risks of the use of bisphosphonates in these unique children at
risk for fracture or bone collapse.